FDA Approves New Interchangeable Biosimilar to Perjeta

On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab. For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.

On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab.

For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.

Posted on 11/14/2025

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington